GPD1L Inhibitors
GPD1L inhibitors are chemical entities that can diminish the functional activity of GPD1L, a protein involved in various signaling processes. These inhibitors cover categories like sodium channel blockers (Quinidine, Flecainide, Lidocaine) to calcium channel blockers (Verapamil, Diltiazem, Nifedipine) and beta-blockers (Propranolol, Metoprolol, Atenolol, Carvedilol, Esmolol, Bisoprolol). Sodium channel blockers like Quinidine, Flecainide, and Lidocaine can indirectly inhibit GPD1L by reducing the sodium current, thereby decreasing the availability of sodium for GPD1L's glycerol-3-phosphate dehydrogenase activity.
Furthermore, calcium channel blockers like Verapamil, Diltiazem, and Nifedipine can indirectly inhibit GPD1L by decreasing the availability of calcium ions. The calcium ions are crucial for the proper functioning of ion channels that GPD1L is known to modulate. Therefore, by reducing calcium ions, these inhibitors can indirectly influence GPD1L'sactivity. Additionally, beta-blockers like Propranolol, Metoprolol, Atenolol, Carvedilol, Esmolol, and Bisoprolol operate by limiting the effect of catecholamines on beta-adrenoceptors, thus impacting the downstream signaling that can influence GPD1L's functional activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Quinidine | 56-54-2 | sc-212614 | 10 g | $102.00 | 3 | |
Quinidine is a voltage-gated sodium channel blocker that can indirectly inhibit GPD1L by reducing the sodium current, decreasing the availability of sodium for GPD1L's glycerol-3-phosphate dehydrogenase activity. | ||||||
Lidocaine | 137-58-6 | sc-204056 sc-204056A | 50 mg 1 g | $50.00 $128.00 | ||
Lidocaine, a local anesthetic, acts as a sodium channel blocker and can indirectly inhibit GPD1L by reducing sodium currents. This decrease in sodium availability can limit GPD1L's glycerol-3-phosphate dehydrogenase activity. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
Verapamil is a calcium channel blocker that can indirectly inhibit GPD1L's function by reducing the availability of calcium ions, which are crucial for the proper functioning of ion channels that GPD1L is known to affect. | ||||||
Diltiazem | 42399-41-7 | sc-204726 sc-204726A | 1 g 5 g | $209.00 $464.00 | 4 | |
Diltiazem, a calcium channel blocker, can indirectly inhibit GPD1L by decreasing the availability of calcium ions, which are necessary for the proper functioning of ion channels that GPD1L is known to modulate. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $58.00 $170.00 | 15 | |
Nifedipine, another calcium channel blocker, can indirectly inhibit GPD1L by reducing the availability of calcium ions. This decrease in calcium can impact the ion channels that GPD1L is known to affect. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol, a non-selective beta-blocker, can indirectly inhibit GPD1L by limiting the effect of catecholamines on beta-adrenoceptors, thereby impacting the downstream signaling that can influence GPD1L's functional activity. | ||||||
Metoprolol Tartrate | 56392-17-7 | sc-205751 sc-205751A | 5 g 25 g | $105.00 $238.00 | 3 | |
Metoprolol, a selective beta1-blocker, can indirectly inhibit GPD1L by dampening the effect of catecholamines on beta1-adrenoceptors, thus impacting the downstream signaling that can influence GPD1L's functional activity. | ||||||
(RS)-Atenolol | 29122-68-7 | sc-204895 sc-204895A | 1 g 10 g | $77.00 $408.00 | 1 | |
Atenolol, another selective beta1-blocker, can indirectly inhibit GPD1L by reducing the effect of catecholamines on beta1-adrenoceptors, thereby impacting the downstream signaling that can influence GPD1L's functional activity. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $122.00 $235.00 $520.00 $979.00 $1500.00 | 2 | |
Carvedilol, a non-selective beta-blocker, can indirectly inhibit GPD1L by reducing the effect of catecholamines on both beta1 and beta2-adrenoceptors, thus reducing the downstream signaling that can influence GPD1L's functional activity. | ||||||
Esmolol | 81147-92-4 | sc-279019B sc-279019A sc-279019 | 50 mg 100 mg 500 mg | $100.00 $150.00 $650.00 | 1 | |
Esmolol, a selective beta1-blocker, can indirectly inhibit GPD1L by reducing the effect of catecholamines on beta1-adrenoceptors, thus impacting the downstream signaling that can influence GPD1L's functional activity. | ||||||